An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer

Table 5 Relationship between clinical factors and RFS in GC patients treated with S-1 adjuvant chemotherapy

Factors	N = 100	Univariate analysis	Multivariate analysis
Factors	N = 100	P-valuea	HR (95% CI)b	P-valueb
Sex (M/F)	73/27	0.821
Age (< 65/≥65 years)	41/59	0.558
Tumor size (< 60/≥60 mm)	48/52	0.093
Histologic type (Diff/Undiff)	35/65	0.199
pT (1/2/3/4)	5/12/41/42	0.226
pN (0/1/2/3)	14/25/31/30	0.014
pStage (II/III)	39/61	0.016
pNLR (+/−)	50/50	0.057
pPLR (+/−)	50/50	0.494
iNLR (+/−)	26/74	0.965
iPLR (+/−)	50/50	0.204
fNLR (+/−)	38/62	< 0.001*	5.309 (2.585–10.901)	< 0.001
fPLR (+/−)	35/65	0.144
CEA (< 5.0/≥5.0 ng/ml)	26/74	0.262
CA19–9 (< 37.0/≥37.0 U/ml)	18/82	0.055

M, male; F, female; Diff, differentiated type; Undiff undifferentiated type; pT, pN, pStage = pathological T stage, N stage. Pathological cancer stage according to the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual; pNLR or pPLR, preoperative neutrophil or platelet-to-lymphocyte ratio; iNLR and iPLR, the ratio of the NLR or PLR on the initial day of adjuvant chemotherapy to the pNLR or pPLR; fNLR and fPLR, the ratio of the NLR or PLR on the final day of adjuvant chemotherapy to the iNLR or iPLR; CEA, carcinoembryonic antigen; CA19–9, carbohydrate antigen 19–9; ^aLog-rank test; ^bCox proportional hazards model; *P-value indicates statistical significance after false discovery rate correction

ISSN: 1471-2407